A large in-frame deletion of the calcium-sensing receptor extracellular domain causes familial hypocalciuric hypercalcaemia type 1 (FHH1) and is partially responsive to cinacalcet
Mendelian randomisation and colocalization analyses reveal novel drug targets for the prevention of kidney stone disease by modulating serum calcium and phosphate concentrations
177Lu-DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic/inoperable phaeochromocytomas and paragangliomas and focus on the impact of genetic variations in SDHx mutation on treatment outcomes – A single centre retrospective analysis of experience at an ENETS Centre of Excellence
Unsupervised steroid metabolome cluster analysis to dissect androgen excess and metabolic dysfunction in 488 women with polycystic ovary syndrome – results from the prospective DAISy-PCOS study.
Medical Research Council London Institute of Medical Sciences (MRC LMS), London, UK
CEJF Best Clinical Abstract: Biological heterogeneity in skeletal susceptibility to glucocorticoid induced bone loss: Short- and long-term BMD trajectories during unopposed GC treatment in adults
CEJF Best Abstract Basic: Single-Cell Analysis for the Human Developing Thyroid Uncovers Thyrocyte Heterogeneity and Active Interactions During Development
Gain-of-function mutation F278C in MC2R results in reduced beta-1-arrestin recruitment and increased cAMP implicating impairment of S280 phosphorylation.
Centre for Endocrinology, William Harvey Research Institute, London, UK
Mild weight loss and activation of RAAS in gene-edited mice with a E958A knock-in mutation in the AF2-LBD domain of the mineralocorticoid receptor gene
Examining latest costs and prescribing on Liothyronine (T3) by dose levels with respect to the 2017 Competition and Market Authority (CMA) investigation into liothyronine prices and the implementation of 2023 British Thyroid Association (BTA) guidance for appropriate patients suggesting Liothyronine daily dose levels of 5-10mcg at possible split dose twice day.
Real-world experience with 11C-methionine PET co-registered with MRI in the management of acromegaly – Insights from a single reference centre 12 year observation
Cambridge Endocrine Molecular Imaging Group, Metabolic Research Laboratories, Wellcome Trust-MRC; Institute of Metabolic Science, University of Cambridge, National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge, UK
Mild weight loss and activation of RAAS in gene-edited mice with a E958A knock-in mutation in the AF2-LBD domain of the mineralocorticoid receptor gene
How to use structural biology to advance your endocrine research
MRC Laboratory of Molecular Biology , Cambridge
Cambridge Endocrine Molecular Imaging Group, Metabolic Research Laboratories, Wellcome Trust-MRC; Institute of Metabolic Science, University of Cambridge, National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge, UK
Real-world experience with 11C-methionine PET co-registered with MRI in the management of acromegaly – Insights from a single reference centre 12 year observation
Cambridge Endocrine Molecular Imaging Group, Metabolic Research Laboratories, Wellcome Trust-MRC; Institute of Metabolic Science, University of Cambridge, National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge, UK
CEJF Best Clinical Abstract: Biological heterogeneity in skeletal susceptibility to glucocorticoid induced bone loss: Short- and long-term BMD trajectories during unopposed GC treatment in adults
Examining latest costs and prescribing on Liothyronine (T3) by dose levels with respect to the 2017 Competition and Market Authority (CMA) investigation into liothyronine prices and the implementation of 2023 British Thyroid Association (BTA) guidance for appropriate patients suggesting Liothyronine daily dose levels of 5-10mcg at possible split dose twice day.
A large in-frame deletion of the calcium-sensing receptor extracellular domain causes familial hypocalciuric hypercalcaemia type 1 (FHH1) and is partially responsive to cinacalcet
Mendelian randomisation and colocalization analyses reveal novel drug targets for the prevention of kidney stone disease by modulating serum calcium and phosphate concentrations
University of Oxford, Oxford, UK
Cardiff University School of Medicine, Cardiff, UK
177Lu-DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic/inoperable phaeochromocytomas and paragangliomas and focus on the impact of genetic variations in SDHx mutation on treatment outcomes – A single centre retrospective analysis of experience at an ENETS Centre of Excellence
Royal Free Hospital, London, UK
Institute of Genetics & Cancer, University of Edinburgh, Edinburgh, UK
CEJF Best Abstract Basic: Single-Cell Analysis for the Human Developing Thyroid Uncovers Thyrocyte Heterogeneity and Active Interactions During Development
Wellcome Sanger Institute, Cambridge, UK
Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford University Hospitals NHS Trust, Oxford, UK
Unsupervised steroid metabolome cluster analysis to dissect androgen excess and metabolic dysfunction in 488 women with polycystic ovary syndrome – results from the prospective DAISy-PCOS study.
Medical Research Council London Institute of Medical Sciences (MRC LMS), London, UK
Nuffield Department of Women’s and Reproductive Health, University of Oxford, Oxford, UK
Gain-of-function mutation F278C in MC2R results in reduced beta-1-arrestin recruitment and increased cAMP implicating impairment of S280 phosphorylation.
Centre for Endocrinology, William Harvey Research Institute, London, UK
Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK
Examining latest costs and prescribing on Liothyronine (T3) by dose levels with respect to the 2017 Competition and Market Authority (CMA) investigation into liothyronine prices and the implementation of 2023 British Thyroid Association (BTA) guidance for appropriate patients suggesting Liothyronine daily dose levels of 5-10mcg at possible split dose twice day.
A large in-frame deletion of the calcium-sensing receptor extracellular domain causes familial hypocalciuric hypercalcaemia type 1 (FHH1) and is partially responsive to cinacalcet
Mendelian randomisation and colocalization analyses reveal novel drug targets for the prevention of kidney stone disease by modulating serum calcium and phosphate concentrations
177Lu-DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic/inoperable phaeochromocytomas and paragangliomas and focus on the impact of genetic variations in SDHx mutation on treatment outcomes – A single centre retrospective analysis of experience at an ENETS Centre of Excellence
Unsupervised steroid metabolome cluster analysis to dissect androgen excess and metabolic dysfunction in 488 women with polycystic ovary syndrome – results from the prospective DAISy-PCOS study.
Medical Research Council London Institute of Medical Sciences (MRC LMS), London, UK
Gain-of-function mutation F278C in MC2R results in reduced beta-1-arrestin recruitment and increased cAMP implicating impairment of S280 phosphorylation.
Centre for Endocrinology, William Harvey Research Institute, London, UK
Mild weight loss and activation of RAAS in gene-edited mice with a E958A knock-in mutation in the AF2-LBD domain of the mineralocorticoid receptor gene
Examining latest costs and prescribing on Liothyronine (T3) by dose levels with respect to the 2017 Competition and Market Authority (CMA) investigation into liothyronine prices and the implementation of 2023 British Thyroid Association (BTA) guidance for appropriate patients suggesting Liothyronine daily dose levels of 5-10mcg at possible split dose twice day.
Real-world experience with 11C-methionine PET co-registered with MRI in the management of acromegaly – Insights from a single reference centre 12 year observation
Cambridge Endocrine Molecular Imaging Group, Metabolic Research Laboratories, Wellcome Trust-MRC; Institute of Metabolic Science, University of Cambridge, National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge, UK
CEJF Best Clinical Abstract: Biological heterogeneity in skeletal susceptibility to glucocorticoid induced bone loss: Short- and long-term BMD trajectories during unopposed GC treatment in adults
CEJF Best Abstract Basic: Single-Cell Analysis for the Human Developing Thyroid Uncovers Thyrocyte Heterogeneity and Active Interactions During Development